Simlandi ® (adalimumab-ryvk) injection, a citrate-free, high-concentration, interchangeable biosimilar to Humira ® (adalimumab), has been made available by Teva and Alvotech. Simlandi is an ...

Almost all patients with nail involvement had polydactylous involvement with onychopapillomas. Alexandra Lebensohn, from the National Institutes of Health in Bethesda, Maryland, and colleagues ...

Patients with moderate to severe plaque psoriasis treated with ixekizumab had significantly greater odds of achieving acceptable response than those treated with other monoclonal antibody biologics. A ...

The United States Justice Department moved to reclassify marijuana as a less dangerous drug, a significant shift in the nation's drug policy. HealthDay News — The U.S. Justice Department on Thursday ...

An increase in cosmetic procedures, especially those performed in developing countries, is associated with a rise in nontuberculous mycobacteria infections. An increase in cosmetic surgical procedures ...

Chatbots can generate quality responses to cancer-related questions, comparable to physician responses. David Chen, from the Princess Margaret Hospital Cancer Centre in Toronto, and colleagues ...

More distinct tumor characteristics, with more advanced disease and worsened outcomes were present in Non-Hispanic Black patients with melanoma. HealthDay News — Non-Hispanic Black (NHB) melanoma ...

Patients with atopic dermatitis treated with crisaborole had a 111-day median duration of flare-free maintenance vs a 30-day duration in those treated with vehicle. Patients with mild to moderate ...

In a small subset of patients, allergic contact dermatitis onset was associated with COVID-19 infection either prior to or post-COVID-19 vaccination. A small percentage of patients may experience ...

Patients with atopic dermatitis should undergo careful corneal monitoring for the potential development of keratoconus. Patients with atopic dermatitis may have a higher risk of developing keratoconus ...

Among patients who had not previously received biologic therapies, treatment with guselkumab demonstrated sustained and consistent improvements over 2 years across critical areas of psoriatic ...

Between 2010 and 2021, only 60.8% of patients with vitiligo in the United Kingdom received treatment for their condition in the first year postdiagnosis, with the number steadily rising to 82% in the ...